Astrazeneca Says Tagrisso Met Primary Endpoint In Phase III AURA3 Trial
July 18, 2016 at 10:43 AM EDT
TAGRISSO is one of the fastest development programs ever, from start of clinical trials to approval in just over two and a half years.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.